Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA447509
Max Phase: Preclinical
Molecular Formula: C43H54N8O8
Molecular Weight: 810.95
Molecule Type: Small molecule
Associated Items:
ID: ALA447509
Max Phase: Preclinical
Molecular Formula: C43H54N8O8
Molecular Weight: 810.95
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N[C@@H](CCCCNC(=O)/C=C/c2cccnc2)C(=O)N[C@@H](CCCC(=O)O)C(=O)NC2(C(N)=O)CCCCC2)cc1
Standard InChI: InChI=1S/C43H54N8O8/c1-29-11-3-4-13-33(29)50-42(59)47-32-20-17-30(18-21-32)27-37(53)48-34(14-5-8-26-46-36(52)22-19-31-12-10-25-45-28-31)39(56)49-35(15-9-16-38(54)55)40(57)51-43(41(44)58)23-6-2-7-24-43/h3-4,10-13,17-22,25,28,34-35H,2,5-9,14-16,23-24,26-27H2,1H3,(H2,44,58)(H,46,52)(H,48,53)(H,49,56)(H,51,57)(H,54,55)(H2,47,50,59)/b22-19+/t34-,35-/m0/s1
Standard InChI Key: OOYFOUHICCOHRQ-CVLSMVSNSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 810.95 | Molecular Weight (Monoisotopic): 810.4065 | AlogP: 4.11 | #Rotatable Bonds: 21 |
Polar Surface Area: 250.81 | Molecular Species: ACID | HBA: 8 | HBD: 8 |
#RO5 Violations: 2 | HBA (Lipinski): 16 | HBD (Lipinski): 9 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.97 | CX Basic pKa: 4.90 | CX LogP: 2.37 | CX LogD: 0.18 |
Aromatic Rings: 3 | Heavy Atoms: 59 | QED Weighted: 0.06 | Np Likeness Score: -0.70 |
1. Carpenter RD, Andrei M, Aina OH, Lau EY, Lightstone FC, Liu R, Lam KS, Kurth MJ.. (2009) Selectively targeting T- and B-cell lymphomas: a benzothiazole antagonist of alpha4beta1 integrin., 52 (1): [PMID:19072684] [10.1021/jm800313f] |
2. Peng L, Liu R, Marik J, Wang X, Takada Y, Lam KS.. (2006) Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging., 2 (7): [PMID:16767086] [10.1038/nchembio798] |
Source(1):